|
Market Closed -
NSE India S.E.
12:05:10 21/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 1,902.40 INR | -0.08% |
|
-1.43% | +10.62% |
| 08-05 | CRISIL Keeps AAA Rating on Sun Pharmaceutical's Bank Facilities | MT |
| 07-31 | Sun Pharmaceutical Industries Limited, Q1 2027 Earnings Call, Jul 31, 2026 |
| Market Cap | 4,564B 47.71B 40.87B 38.24B 35B 65.69B 66.55B 452B 176B 2,293B 179B 175B 7,584B | P/E 2027 * |
35.1x | P/E 2028 * | 29.7x |
|---|---|---|---|---|---|
| Enterprise Value | 4,285B 44.79B 38.37B 35.9B 32.86B 61.67B 62.49B 424B 165B 2,153B 168B 165B 7,121B | EV / Sales 2027 * |
6.58x | EV / Sales 2028 * | 5.78x |
| Free-Float |
44.39% | Yield 2027 * |
0.9% | Yield 2028 * | 1.04% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -0.08% | ||
| 1 week | -1.43% | ||
| Current month | -4.43% | ||
| 1 month | -3.03% | ||
| 3 months | +0.59% | ||
| 6 months | +10.32% | ||
| Current year | +10.62% |
| 1 week | 1,868.3 |  | 1,949.8 |
| 1 month | 1,868.3 | | 2,046.9 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,548 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 31/08/2025 | |
| Director of Finance/CFO | 58 | 30/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 31/08/2025 | |
| Director/Board Member | 73 | 24/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.08% | -1.43% | +15.99% | +67.26% | 47.71B | |
| -3.21% | +1.37% | +52.36% | +125.75% | 40.3B | |
| -0.40% | -1.23% | -10.08% | +16.08% | 12.09B | |
| +1.11% | -1.34% | +13.61% | +71.49% | 11.68B | |
| 0.00% | +0.58% | +30.65% | +148.80% | 9.19B | |
| -0.39% | -0.92% | +19.81% | +39.54% | 7.57B | |
| -1.35% | +0.74% | +47.03% | -11.93% | 7.24B | |
| -0.64% | -0.02% | +19.42% | +199.06% | 6.84B | |
| -5.36% | -6.36% | -36.28% | +18.28% | 5.42B | |
| -0.51% | -0.90% | +37.01% | +103.41% | 4.75B | |
| Average | -1.08% | -1.03% | +18.95% | +77.78% | 15.28B | |
| Weighted average by Cap. | -1.14% | -0.72% | +24.83% | +84.03% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.8B 5.83B 5.45B 4.99B 9.37B 9.49B 64.42B 25.12B 327B 25.54B 24.99B 1,082B | 729B 7.62B 6.52B 6.1B 5.59B 10.49B 10.63B 72.12B 28.12B 366B 28.6B 27.98B 1,211B |
| Net income | 130B 1.36B 1.17B 1.09B 998M 1.87B 1.9B 12.88B 5.02B 65.38B 5.11B 5B 216B | 154B 1.61B 1.38B 1.29B 1.18B 2.22B 2.25B 15.26B 5.95B 77.46B 6.05B 5.92B 256B |
| Net Debt | -279B -2.92B -2.5B -2.34B -2.14B -4.02B -4.07B -27.62B -10.77B -140B -10.95B -10.71B -464B | -349B -3.65B -3.13B -2.92B -2.68B -5.02B -5.09B -34.56B -13.48B -175B -13.7B -13.4B -580B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/08/26 | ₹1,902.40 | -0.08% | 1,491,953 |
| 20/08/26 | ₹1,904.00 | +0.21% | 893,691 |
| 19/08/26 | ₹1,900.00 | +1.33% | 1,566,692 |
| 18/08/26 | ₹1,875.10 | -0.37% | 1,819,169 |
| 17/08/26 | ₹1,882.00 | -2.49% | 1,893,086 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
